Table 3 Patient characteristics by time to diagnosis of recurrence of breast cancer in luminal subgroup
From: Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer
Time to recurrence | Total (n = 206) | p | |||
|---|---|---|---|---|---|
<5 years (n = 101) | ≥5 years (n = 105) | ||||
Mean age, years (SD) | 49.17 (10.5) | 48.45 (10.6) | 206 | 0.562 | |
Menopausal status | Pre/peri-menopause | 74 (73.2) | 71 (67.6) | 145 | 0.377 |
Postmenopause | 27 (26.8) | 34 (32.4) | 61 | ||
T stage | ≤2 cm | 19 (18.9) | 42 (40.0) | 61 | 0.001 |
>2 cm | 82 (81.1) | 63 (60.0) | 145 | ||
N stage | Node-negative | 29 (28.7) | 59 (56.2) | 88 | <0.001 |
Node-positive | 72 (71.3) | 46 (43.8) | 118 | ||
Grade (n = 174) | 1 | 9 (9.4) | 15 (18.9) | 24 | 0.019 |
2 | 59 (62.1) | 51 (64.5) | 110 | ||
3 | 27 (28.5) | 13 (16.6) | 40 | ||
Lymphovascular invasion (n = 176) | Yes | 59 (62.1) | 42 (51.8) | 101 | 0.172 |
No | 36 (37.9) | 39 (48.2) | 75 | ||
ER titer (n = 156) | High (≥50 %) | 67 (81.7) | 72 (97.2) | 139 | 0.002 |
Low (<50 %) | 15 (18.3) | 2 (2.8) | 17 | ||
ER− or PR− | 26 (25.7) | 4 (3.8) | 30 | <0.001 | |
HER2+ | 25 (24.7) | 3 (2.8) | 28 | <0.001 | |
Adjuvant therapy | None | 4 (3.9) | 2 (1.9) | 6 | 0.047 |
Chemotherapy | 7 (6.9) | 7 (6.6) | 14 | ||
Endocrine therapy | 17 (16.8) | 35 (33.3) | 52 | ||
Chemo-endocrine | 73 (72.4) | 61 (58.2) | 154 | ||